FDA Approves Severe Hair Loss Drug | City of health Berlin

Friday 17 June 2022 – Author: ham

The U.S. Food and Drug Administration (FDA) has approved the drug baricitinib for severe hair loss. The active ingredient has so far been used for Covid-19 and rheumatoid arthritis. Studies show that the tablet is also effective for alopecia.

Hair loss can be very painful. A new drug is giving hope. A few days ago in the USA the drug baricitinib was approved for the treatment of severe forms of alopecia. Alopecia means “hairless”. In severe cases, this means a completely bald head.

Baricitinib regulates inflammatory responses

The JAK baricitinib inhibitor (OLUMIANT) has been approved for the treatment of rheumatoid arthritis since 2017 due to its anti-inflammatory effect. The active ingredient has also received emergency approval for in-hospital treatment of oxygen-dependent Covid patients.

80 percent of the hair has grown back

Two studies involving a total of 1,200 adults with severe alopecia showed that the tablet is also effective for alopecia. After 36 weeks of treatment, 80% of the hair had regrown in one in three study participants at the highest dose: 4 mg per day. In the group with the lowest dosage – 2 mg per day – this success occurred in every fourth participant. In the placebo group, it was only 5%. Patients with loss of eyelashes or eyebrows also benefited from baricitinib 4 mg per day.

Approval of the drug baricitinib “will help meet a significant unmet need for patients with severe alopecia areata,” said Kendall Marcus, director of dermatology at the FDA.

Not without side effects

The most common side effects of baricitinib included upper respiratory tract infections, headache, nausea, fatigue, and changes in blood counts. It is still unclear whether baricitinib will also be approved in Europe for the treatment of severe alopecia.

About the author


Leave a Comment